Dr. Adam B. Shrewsberry, MD

Dr. Shrewsberry practices at Physicians Regional Medical Center (Closed) in Knoxville, Tennessee.

Dr. Shrewsberry's NPI, 1295977783, was assigned on March 30, 2009. Dr. Shrewsberry graduated from Emory University School of Medicine in 2014. Dr. Shrewsberry holds Tennessee license 51315.

Dr. Shrewsberry's primary practice is Physicians Regional Medical Center (Closed), at 900 W Oak Hill Ave, Knoxville, TN 37921 in Knox County. The practice phone is (865) 545-8000.

Dr. Shrewsberry's primary practice is Physicians Regional Medical Center (Closed) in Knoxville, Tennessee. Dr. Shrewsberry is also affiliated with Tennova North Knoxville Medical Center. The medical group on file is CORA Physical Therapy. Dmand AI also links Dr. Shrewsberry to 4 more hospitals, 2 group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shrewsberry practices, 8 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Shrewsberry's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dmand AI has Dr. Shrewsberry's licenses on file in 2 states: Tennessee and Georgia.

CMS data shows 5,766 Medicare services from Dr. Shrewsberry across 31 procedure codes in 2024, for 1,578 Medicare patients. Medicare paid $426,409 for them.

CMS counts 1,578 Medicare patients who saw Dr. Shrewsberry in 2024. The largest group is 65 to 74, with 752 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.19, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Shrewsberry's median patient age at 72, with 30% women.

In 2024, Dr. Shrewsberry wrote 6,212 Medicare Part D claims for 1,751 patients. 76% of them were for generic drugs. CMS names the drug for 6,085 of them, across 28 drugs with 11 or more claims each, at $863,701 in total drug cost. In 2023, CMS named 4,293 claims across 24 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Shrewsberry for performance year 2024, reported through an alternative payment model (APM). Dr. Shrewsberry accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 33 procedures of prostate resection by Dr. Shrewsberry, more than 93% of the clinicians it reports for that procedure.

Dmand AI links 11 papers to Dr. Shrewsberry, published from 2011 to 2016. 2014 was the busiest year, with 2. The most frequent topics are Kidney Neoplasms, Carcinoma, Renal Cell and Magnetic Resonance Imaging. Dr. Shrewsberry has published most often in Can J Urol. Dr. Shrewsberry's most frequent co-authors are Chad Wesley Mark Ritenour, MD, Paymon Nourparvar, MD and Daniel J. Canter, MD.

CMS Open Payments shows 317 general payments to Dr. Shrewsberry from 58 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 93% of the total. Astellas Pharma US Inc paid the most, $881.

Dr. Shrewsberry graduated from Emory University School of Medicine in 2014.